NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer

Author:
Wells A. Messersmith
Search for other papers by Wells A. Messersmith in
Current site
Google Scholar
PubMedClose
 MD
Volume/Issue:
Volume 17: Issue 5.5
Online Publication Date:
May 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5014
Restricted access

In the last year, several impactful updates have been added to the NCCN Guidelines for Colorectal Cancer (CRC) for the management of metastatic disease, including additional options for BRAF-mutated advanced CRC and the inclusion of combination immunotherapy (PD-1 and CTLA-4) for deficient mismatch repair/microsatellite instability (MSI)–high advanced CRC. According to Dr. Wells A. Messersmith, targeted therapies (ie, VEGFR, EGFR, multitargeted tyrosine kinase inhibitors) play an important role in CRC management, but none of them have been successful in the adjuvant setting (although checkpoint inhibition is now being tested in MSI-high stage III CRC). Reliable predictive biomarkers for most agents are still greatly lacking, highlighting the importance of investing in CRC biomarker studies.

Correspondence: Wells A. Messersmith, MD, Gastrointestinal Medical Oncology Program, University of Colorado School of Medicine, 12801 East 17th Avenue, L18-8124, Mail Stop 8117, Aurora, CO 80045. Email: wells.messersmith@ucdenver.edu
  • Collapse
  • Expand
  • 1.

    American Cancer Society. Cancer Facts & Figures, 2018. Atlanta, GA: American Cancer Society; 2018.

  • 2.

    Lenz HJ, Ou SF, Venook AP, et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 3511.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Geissler M, Riera-Knorrenschild J, Tannapfel A, et al. mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109) [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 3509.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–2520.

  • 5.

    Drilon A, Laetsch TW, Kummar S et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.

  • 6.

    Atreya CE, Van Custem E, Bendell JC, et al. Phase 1/2 Study of the MEK inhibitor trametinib, BRAF inhibitor dabrafenib, and anti-EGFR antibody panitumumab in patients with BRAF V600E-mutated metastatic colorectal cancer [abstract]. J Clin Oncol 2015:33(Suppl):Abstract 103.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Kopetz S, Grothey A, Yaeger R, et al. Updated results of the BEACON CRC safety lead-in: encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 688.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Corcoran RB, André T, Atreya CE, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 2018;8:428–443.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2019
Online Publication Date:
May 2019
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 12566 2406 196
PDF Downloads 7340 2246 215
EPUB Downloads 0 0 0